|Bid||37.88 x 2900|
|Ask||37.89 x 900|
|Day's range||37.77 - 38.58|
|52-week range||27.88 - 40.97|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||14.97|
|Earnings date||27 Oct 2020 - 02 Nov 2020|
|Forward dividend & yield||1.52 (3.96%)|
|Ex-dividend date||30 Jul 2020|
|1y target est||41.85|
Latest news and updates and the global coronavirus pandemic.
The coronavirus pandemic has the world's drugmakers working together to deliver medical solutions and some companies are poised to contribute more than others. With a coronavirus vaccine candidate in late-stage clinical trials and a contract to help manufacture the only COVID-19 antiviral treatment available at the moment, Pfizer (NYSE: PFE) is contributing more than the vast majority of its big pharma peers. Do Pfizer's contributions to the fight against the COVID-19 pandemic make it a good stock to buy right now?
Ladies and gentlemen, thank you for standing by and welcome to Q2 2020 ICU Medical, Inc. Earnings Conference Call. Thank you for joining us today to discuss the ICU Medical financial results for the second quarter of 2020. On the call today representing ICU Medical is Vivek Jain, Chief Executive Officer and Chairman and Brian Bonnell, Chief Financial Officer.